The posting of sponsored information and content on this page should not be considered an AAFP endorsement or recommendation of the sponsor's products, services, policies, or procedures. The information and opinions expressed on this page are those of the paid sponsors and do not necessarily reflect the view of the AAFP. The AAFP is not responsible for the content of third-party websites linked from this page; moreover, any links on this page to third-party websites where goods or services are advertised are not endorsements or recommendations by the AAFP of the third-party sites, goods, or services.
VASCEPA® (icosapent ethyl) CV Outcomes Trial Results
Free handout provided by Amarin Pharma, Inc.
The effects of VASCEPA® (icosapent ethyl) on the prevention of cardiovascular events was evaluated in a multi-center, double-blind, randomized, placebo-controlled, event-driven trial (REDUCE-IT) in 8,179 adult patients at LDL-C goal, with established cardiovascular disease (CVD) or at high risk for CVD, and hypertriglyceridemia (fasting TG ≥135 and <500 mg/dL).
REDUCE-IT results were first presented as a late-breaker on November 10, 2018 in Chicago, Illinois and concurrently published online. See the publication at www.NEJM.org(www.nejm.org).
FDA has not reviewed and opined on a supplemental new drug application related to REDUCE-IT. FDA has thus not reviewed the information herein or determined whether to approve VASCEPA for use to reduce the risk of major adverse cardiovascular events in the REDUCE-IT patient population. This information is intended to ensure Amarin meets its continuing obligation to update healthcare professionals regarding off-label use of VASCEPA to assure that its communications remain truthful and non-misleading, consistent with the federal court approved settlement under Amarin Pharma, Inc. et al. v. United States Food and Drug Administration et al., 119 F.Supp.3d 196, 236 (S.D.N.Y. 2015).
FDA-Approved Indication and Limitations of Use for VASCEPA
- VASCEPA® (icosapent ethyl) is indicated as an adjunct to diet to reduce TG levels in adult patients with severe (>500 mg/dL) hypertriglyceridemia
- In patients with severe hypertriglyceridemia, the effect of VASCEPA on cardiovascular mortality or morbidity or on the risk of pancreatitis has not been determined
Important Safety Information for VASCEPA from FDA-Approved Label Data from Two 12-Week Studies (MARINE and ANCHOR) of Patients with TG Values of 200 to 2000 mg/dL (n=622 on VASCEPA, n=309 on placebo)
- VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components
- In patients with hepatic impairment, monitor ALT and AST levels periodically during therapy
- Use with caution in patients with known hypersensitivity to fish and/or shellfish
- The most common reported adverse reaction (incidence >2% and greater than placebo) was arthralgia (2.3% VASCEPA, 1.0% placebo)
- Adverse events may be reported by calling 1-855-VASCEPA or the FDA at 1 800 FDA 1088
- Patients receiving treatment with VASCEPA and other drugs affecting coagulation (e.g., anti-platelet agents) should be monitored periodically
- Patients should be advised to swallow VASCEPA capsules whole; not to break open, crush, dissolve, or chew VASCEPA